STOCK TITAN

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET. Bill Lundberg, M.D., the President and CEO, will represent the clinical-stage oncology company known for developing innovative multispecific antibodies, including Biclonics® and Triclonics®. A webcast of the event can be accessed on the Company's Investors page, and an archived version will be available post-event.

Loading...
Loading translation...
Argus Session date unavailable
+11.28% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was +11.28%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET.

The webcast of the fireside chat will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Merus N.V. participating in the Jefferies Healthcare Conference?

Merus N.V. will participate in the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET.

Who will represent Merus N.V. at the Jefferies Healthcare Conference?

Bill Lundberg, M.D., President and CEO of Merus N.V., will represent the company at the conference.

Where can I watch the Merus N.V. fireside chat from the Jefferies Healthcare Conference?

The fireside chat can be watched live on the Investors page of Merus N.V.'s website.

What is the stock symbol for Merus N.V.?

The stock symbol for Merus N.V. is MRUS.

What type of therapies does Merus N.V. focus on?

Merus N.V. focuses on developing innovative full-length multispecific antibodies for oncology.

Keep reading